Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/two-year-clinical-outcome-after-implantation-of-sirolimus-eluting-and-h6wNXuQdL3
References (40)
-
F. Song, D. Altman, A. Glenny, J. Deeks (2003)
Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJ : British Medical Journal, 326
-
S. Elezi, A. Kastrati, J. Pache, A. Wehinger, M. Hadamitzky, J. Dirschinger, Franz‐Josef Neumann, A. Schömig (1998)
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.Journal of the American College of Cardiology, 32 7
-
P. Kuchulakanti, William Chu, R. Torguson, P. Ohlmann, S. Rha, L. Clavijo, Sang-Wook Kim, A. Bui, N. Gevorkian, Zhenyi Xue, Kimberly Smith, J. Fournadjieva, W. Suddath, L. Satler, A. Pichard, K. Kent, R. Waksman (2006)
Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting StentsCirculation, 113
-
E. Belle, Marc Périé, D. Braune, A. Chmaït, T. Meurice, K. Abolmaali, E. Mcfadden, C. Bauters, J. Lablanche, M. Bertrand (2002)
Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients.Journal of the American College of Cardiology, 40 3
-
Joachim Schofer, Michael Schlüter, Thomas Rau, Falk Hammer, Natalie Haag, D. Mathey (2000)
Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study.Journal of the American College of Cardiology, 35 6
-
iii) The therapeutic benefit of SES over PES in diabetic patients was maintained over 2 years of follow-up -
A. Dibra, A. Kastrati, J. Mehilli, J. Pache, H. Schühlen, N. Beckerath, K. Ulm, R. Wessely, J. Dirschinger, A. Schömig (2005)
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.The New England journal of medicine, 353 7
-
(2006)
Integrated analysis of medically treated diabetic patients in the TAXUS program -
of SES and -
G. Stone, J. Moses, S. Ellis, J. Schofer, K. Dawkins, M. Morice, A. Colombo, E. Schampaert, E. Grube, A. Kirtane, D. Cutlip, M. Fahy, S. Pocock, R. Mehran, M. Leon (2007)
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.The New England journal of medicine, 356 10
-
J. Mehilli, A. Dibra, A. Kastrati, J. Pache, J. Dirschinger, A. Schömig (2006)
Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.European heart journal, 27 3
-
M. Sabaté, P. Jiménez-Quevedo, D. Angiolillo, J. Gomez-Hospital, F. Alfonso, R. Hernández-Antolı́n, J. Goicolea, C. Bañuelos, J. Escaned, R. Moreno, C. Fernández, F. Fernández‐Avilés, C. Macaya (2005)
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) TrialCirculation, 112
-
A. Kastrati, J. Mehilli, N. Beckerath, A. Dibra, J. Hausleiter, J. Pache, H. Schühlen, C. Schmitt, J. Dirschinger, A. Schömig (2005)
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.JAMA, 293 2
-
G. Stanković, J. Cosgrave, A. Chieffo, I. Iakovou, G. Sangiorgi, M. Montorfano, F. Airoldi, M. Carlino, I. Michev, L. Finci, A. Colombo (2006)
Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery.The American journal of cardiology, 98 3
-
C. Stettler, S. Allemann, Matthias Egger, S. Windecker, B. Meier, P. Diem (2005)
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trialsHeart, 92
-
Two-year clinical outcome after implantation of SES and PES -
M. Morice, P. Serruys, J. Sousa, J. Fajadet, E.Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi, F. Molnár, R. Falotico (2002)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.The New England journal of medicine, 346 23
-
G. Stone, S. Ellis, D. Cox, J. Hermiller, C. O'shaughnessy, J. Mann, M. Turco, R. Caputo, P. Bergin, Joel Greenberg, J. Popma, M. Russell (2004)
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.The New England journal of medicine, 350 3
-
J. Daemen, H. Garcia-Garcia, N. Kukreja, Farshad Imani, P. Jaegere, G. Sianos, R. Domburg, P. Serruys (2006)
The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus.European heart journal, 28 1
-
A. Colombo, J. Drzewiecki, A. Banning, E. Grube, K. Hauptmann, S. Silber, D. Dudek, S. Fort, F. Schiele, K. Zmudka, G. Guagliumi, M. Russell (2003)
Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation: Journal of the American Heart Association, 108
-
(2005)
Drug - eluting stents for complex lesions : randomized rapamycin versus paclitaxel CORPAL study -
J. Moses, M. Leon, J. Popma, P. Fitzgerald, D. Holmes, C. O'shaughnessy, R. Caputo, D. Kereiakes, David Williams, P. Teirstein, Judith Jaeger, R. Kuntz (2003)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.The New England journal of medicine, 349 14
-
i) Diabetic patients have worse prognosis than non-diabetic patients undergoing PCI with DES -
J. Hermiller, A. Raizner, L. Cannon, P. Gurbel, M. Kutcher, S. Wong, M. Russell, Stephen Ellis, R. Mehran, G. Stone (2005)
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.Journal of the American College of Cardiology, 45 8
-
M. Togni, S. Eber, J. Widmer, M. Billinger, P. Wenaweser, S. Cook, R. Vogel, C. Seiler, F. Eberli, W. Maier, R. Corti, M. Roffi, T. Lüscher, A. Garachemani, O. Hess, Simon Wandel, B. Meier, P. Jüni, S. Windecker (2007)
Clinical ResearchInterventional CardiologyImpact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX TrialJournal of the American College of Cardiology, 50
-
C. Stettler, Simon Wandel, S. Allemann, A. Kastrati, M. Morice, A. Schömig, M. Pfisterer, G. Stone, M. Leon, J. Lezo, J. Goy, Seung‐Jung Park, M. Sabaté, M. Suttorp, H. Kelbaek, C. Spaulding, M. Menichelli, P. Vermeersch, M. Dirksen, P. Červinka, A. Petronio, A. Nordmann, P. Diem, B. Meier, M. Zwahlen, S. Reichenbach, S. Trelle, S. Windecker, P. Jüni (2007)
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisThe Lancet, 370
-
S. Woodfield, C. Lundergan, J. Reiner, S. Greenhouse, M. Thompson, S. Rohrbeck, Y. Deychak, M. Simoons, R. Califf, E. Topol, A. Ross (1996)
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.Journal of the American College of Cardiology, 28 7
-
R. Kornowski, G. Mintz, K. Kent, A. Pichard, L. Satler, T. Bucher, M. Hong, J. Popma, M. Leon (1997)
Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study.Circulation, 95 6
-
ii) SES more effectively reduce the rates of MACE and TLR than PES in diabetic patients -
A. Ong, J. Aoki, C. Mieghem, Gastón Granillo, M. Valgimigli, K. Tsuchida, K. Sonnenschein, E. Regar, W. Giessen, P. Jaegere, G. Sianos, E. Mcfadden, P. Feyter, R. Domburg, P. Serruys (2005)
Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries).The American journal of cardiology, 96 3
-
G. Stone, S. Ellis, L. Cannon, J. Mann, Joel Greenberg, D. Spriggs, C. O'shaughnessy, Samuel DeMaio, Patrick Hall, J. Popma, J. Koglin, Mary Russell (2005)
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.JAMA, 294 10
-
C. Spaulding, J. Daemen, E. Boersma, D. Cutlip, P. Serruys (2007)
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.The New England journal of medicine, 356 10
-
M. Morice, A. Colombo, B. Meier, P. Serruys, C. Tamburino, G. Guagliumi, E. Sousa, H. Stoll (2006)
Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.JAMA, 295 8
-
Young-Hak Kim, Seong-Wook Park, Seung‐Whan Lee, Duk‐Woo Park, S. Yun, Cheol-Whan Lee, M. Hong, Hyun-Sook Kim, J. Ko, Jae‐Hyeong Park, Jae‐Hwan Lee, Si-Wan Choi, I. Seong, Y. Cho, N. Lee, J. Kim, K. Chun, Seung‐Jung Park (2006)
Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery DiseaseCirculation, 114
-
P. Kuchulakanti, William Chu, R. Torguson, L. Clavijo, R. Wolfram, Sundeep Mishra, Zhenyi Xue, N. Gevorkian, W. Suddath, L. Satler, K. Kent, A. Pichard, R. Waksman (2006)
Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus.The American journal of cardiology, 98 2
-
A. Abizaid, R. Kornowski, G. Mintz, M. Hong, A. Abizaid, R. Mehran, A. Pichard, K. Kent, L. Satler, Hongsheng Wu, J. Popma, M. Leon (1998)
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.Journal of the American College of Cardiology, 32 3
-
S. Elezi, A. Dibra, J. Mehilli, J. Pache, R. Wessely, A. Schömig, A. Kastrati (2006)
Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.Journal of the American College of Cardiology, 48 7
-
A. Kastrati, A. Dibra, J. Mehilli, S. Mayer, S. Pinieck, J. Pache, J. Dirschinger, A. Schömig (2006)
Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting StentsCirculation, 113
-
S. Windecker, A. Remondino, F. Eberli, P. Jüni, L. Räber, P. Wenaweser, M. Togni, M. Billinger, D. Tüller, C. Seiler, M. Roffi, R. Corti, G. Sütsch, W. Maier, T. Lüscher, O. Hess, M. Egger, B. Meier (2005)
Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.The New England journal of medicine, 353 7
-
R. Mehran, G. Dangas, Yoshio Kobayashi, A. Lansky, G. Mintz, E. Aymong, M. Fahy, J. Moses, G. Stone, M. Leon (2004)
Short- and long-term results after multivessel stenting in diabetic patients.Journal of the American College of Cardiology, 43 8
- Publisher
- Oxford University Press
- Copyright
- © Published by Oxford University Press.
- Subject
- CLINICAL RESEARCH
- ISSN
- 0195-668X
- eISSN
- 1522-9645
- DOI
- 10.1093/eurheartj/ehn021
- pmid
- 18272504
- Publisher site
- See Article on Publisher Site
Abstract
AimsPercutaneous coronary intervention (PCI) in diabetic patients is associated with an increased risk of restenosis and major adverse cardiac events (MACE). We assessed the impact of diabetes on long-term outcome after PCI with sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents.Methods and resultsIn the SIRTAX trial, 1012 patients were randomized to treatment with SES (n 503) or PES (n 509). A stratified analysis of outcomes was performed according to the presence or absence of diabetes. Baseline characteristics were well balanced between SES and PES in patients with (N 201) and without diabetes (N 811). Clinical outcome was worse in diabetic compared with non-diabetic patients regarding death (9.0 vs. 4.1, P 0.004) and MACE (defined as cardiac death, myocardial infarction, or TLR; 19.9 vs. 12.7, P 0.007) at 2 years. Among diabetic patients, SES reduced MACE by 47 (14.8 vs. 25.8, HR 0.52, P 0.05) and TLR by 61 (7.4 vs. 17.2, HR 0.39, P 0.03) compared with PES at 2 years.ConclusionDiabetic patients have worse prognosis than non-diabetic patients undergoing PCI with DES. Among the diabetic patient population of this trial, SES reduce repeat revascularization procedures and MACE more effectively than PES and to a similar degree as in non-diabetic patients.
Journal
European Heart Journal – Oxford University Press
Published: Mar 12, 2008
Keywords: Keywords Coronary disease Stents Drugs Restenosis Diabetes